皮肤改善可预示早期弥漫性系统性硬化症其他器官系统的有利变化
该研究基于加拿大硬皮病研究组数据库,纳入病程≤5年、无初始终末期器官损害的早期弥漫性皮肤型系统性硬化症(dcSSc)患者,分析1年(n=154)和2年(n=128)随访中改良Rodnan皮肤评分(mRSS)变化与其他器官受累严重程度变化的关系。结果显示,mRSS改善与肺功能下降更少、新发心脏受累更少以及肺、外周血管和关节/肌腱受累更好相关,mRSS恶化则与肺部结局不利和2年时更严重的胃肠道疾病相关。结论认为皮肤变化与肺功能变化密切平行,mRSS改善反映内脏疾病预后更好。
要点
- 早期dcSSc中mRSS改善与1年肺功能下降更少和新发心脏受累更少相关。
- mRSS改善与2年时肺、外周血管和关节/肌腱受累更好相关。
- mRSS恶化与1年和2年肺部结局不利及2年胃肠道疾病更严重相关。
核心结论
- 早期dcSSc中皮肤变化与肺功能变化密切平行,mRSS改善反映内脏疾病预后更好。
研究设计与样本
- 基于加拿大硬皮病研究组数据库,纳入病程≤5年、无初始终末期器官损害和/或显著合并症的dcSSc患者,1年随访n=154、2年随访n=128。
- mRSS变化25%和/或≥5分视为显著,器官受累采用Medsger疾病严重度评分和加拿大硬皮病研究组定义评估。
- 采用双变量、卡方、ANOVA、校正回归和纵向混合效应模型分析。
主要发现
- 1年时41%患者mRSS改善,2年时50%患者mRSS改善。
- 改善患者1年内用力肺活量下降更少(P=0.012),新发心脏受累更少(P=0.02)。
- 改善患者2年内肺受累更好(疾病严重度评分P=0.006,Δ用力肺活量% P=0.026),外周血管受累更好(P=0.006),关节/肌腱受累更好(P=0.002)。
- mRSS恶化在1年和2年随访均与更不利的肺部结局相关,2年时与更严重的胃肠道疾病相关。
关键数值与推荐
- mRSS变化25%和/或≥5分视为显著。
- 器官受累评估采用Medsger疾病严重度评分和加拿大硬皮病研究组定义。
临床怎么用
- 在早期dcSSc中,mRSS改善可作为内脏疾病预后更好的可靠指标,支持其作为临床试验结局指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Skin improvement in diffuse cutaneous SSc (dcSSc), measured with modified Rodnan skin score (mRSS), is frequently used as a primary outcome in clinical trials, but it is uncertain whether mRSS changes reflect changes in other organ systems. This aim of this study was to explore if skin changes in early dcSSc over 1 and 2 years are associated with changes in severity of other organ involvement. METHODS: Canadian Scleroderma Research Group database patients with dcSSc, disease duration of ≤5 years, no evidence of initial end-stage organ damage and/or significant comorbidity who had 1 year (n = 154) and 2 years (n = 128) of follow-up data were included. mRSS changes of 25% and/or ≥5 points were considered significant. Organ involvement was assessed by Medsger Disease Severity Score and Canadian Scleroderma Research Group definitions using bivariate, chi-square, ANOVA, adjusted regression and longitudinal mixed effect model analyses. RESULTS: Improvement in mRSS was found in 41% of patients at 1 year and in 50% at 2 years. Improved patients showed less forced vital capacity decline (P = 0.012) and less frequent new cardiac involvement (P = 0.02) over 1 year, as well as better lung (by both Disease Severity Score, P = 0.006, and Δforced vital capacity%, P = 0.026), peripheral vascular (P = 0.006) and joint/tendon (P = 0.002) involvement over 2 years. mRSS worsening was consistently linked to less favourable lung outcomes at both 1- and 2-year follow-up visits, and more severe gastrointestinal disease at 2 years. CONCLUSION: Changes in lung function in early dcSSc closely parallel skin changes. mRSS improvement reflects better prognosis for visceral disease and may be a reliable outcome measure in clinical trials.
引用
- Nevskaya T, Zheng B, Baxter CA, et al. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2020. PMID: 31774531. doi:10.1093/rheumatology/kez529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。